Active, not recruitingNCT04707235
ESCORT-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study
Studying Sickle cell disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Theravia
- Principal Investigator
- Mariane de Montalembert, MD, PhDHospital Necker enfants malades
- Intervention
- Hydroxycarbamide(drug)
- Enrollment
- 2093 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2020 – 2025
Study locations (30)
- Amiens - Picardie Hospital Adults, Amiens, France
- Amiens Picardie Hospital Children, Amiens, France
- Clinique de l'Europe Amiens, Amiens, France
- Angers Hospital Adults, Angers, France
- Angers Hospital Center Children, Angers, France
- Robert Ballanger Hospital Adults, Aulnay-sous-Bois, France
- Robert Ballanger Hospital Children, Aulnay-sous-Bois, France
- Avicenne Hospital Adults, Bobigny, France
- Jean Verdier Hospital Children, Bondy, France
- Bordeaux Hospital Adults, Bordeaux, France
- Bordeaux Hospital Children, Bordeaux, France
- Ambroise Paré Hospital Children, Boulogne-Billancourt, France
- Tours Regional University Hospital Center Adults, Chambray-lès-Tours, France
- Estaing Hospital Children, Clermont-Ferrand, France
- Louis Mourier Hospital Adults, Colombes, France
- +15 more locations on ClinicalTrials.gov
Collaborators
International Clinical Trials Association
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04707235 on ClinicalTrials.govOther trials for Sickle cell disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE4NCT06979492Prophylactic Transfusion In Pregnant in Women With Sickle Cell DiseaseEmory University
- RECRUITINGNCT07392216Functional Ovarian Reserve in Sickle Cell DiseaseSt. Jude Children's Research Hospital
- RECRUITINGNANCT07246265Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive CareUniversity Hospital, Tours
- ENROLLING BY INVITATIONPHASE2NCT07401823Open-Label Extension Study to Pioneer Study 6058-SCD-101Fulcrum Therapeutics
- RECRUITINGPHASE1, PHASE2NCT07432867Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA.Assistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT07222475Writing Relaxing Beats in Adolescents Who Have Sickle Cell DiseaseMayo Clinic
- RECRUITINGPHASE2NCT07224360Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)CSL Behring
- RECRUITINGPHASE3NCT07247188Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell DiseaseSanofi